Skip to main content

Advertisement

Log in

High-Dose Dexamethasone Inhibits BAFF Expression in Patients with Immune Thrombocytopenia

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Introduction

B-cell activating factor belonging to the TNF family (BAFF) is elevated in several autoimmune diseases including immune thrombocytopenia (ITP). High-dose dexamethasone (HD-DXM) has shown its clinical efficacy in ITP patients.

Materials and Methods

The plasma BAFF concentration and BAFF mRNA were measured in ITP patients before and after oral administration of 40 mg/day DXM for four consecutive days by enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR. Moreover, we evaluated the effects of DXM on BAFF expression and proliferation of lymphocytes by ELISA, real-time quantitative PCR and cell proliferation respectively in in vitro experiment.

Results

Both plasma BAFF concentration and BAFF mRNA were significantly increased in active ITP patients at pretherapy when compared with controls (P < 0.001). After 4-day treatment with HD-DXM, the BAFF and BAFF mRNA were decreased, and lower than that for controls. In in vitro assays, we found DXM-inhibited BAFF, IFN-γ expression, and the proliferation of lymphocytes in a dose-dependent manner.

Conclusion

These results suggest that BAFF expression is increased in ITP patients with active disease, and DXM is an effective inhibitor of BAFF production. As immunosuppressant, DXM may play its role in ITP treatment partly through regulating BAFF expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood. 1993;81:1246–50.

    PubMed  CAS  Google Scholar 

  2. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest. 1998;102:1393–402. doi:10.1172/JCI4238.

    Article  PubMed  CAS  Google Scholar 

  3. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747–56. doi:10.1084/jem.189.11.1747.

    Article  PubMed  CAS  Google Scholar 

  4. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–3. doi:10.1126/science.285.5425.260.

    Article  PubMed  CAS  Google Scholar 

  5. Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. J Immunol. 2001;167:6225–31.

    PubMed  CAS  Google Scholar 

  6. Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol. 2005;174:5537–44.

    PubMed  CAS  Google Scholar 

  7. Kalled SL, Ambrose C, Hsu YM. The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun. 2005;8:206–42. doi:10.1159/000082105.

    Article  PubMed  CAS  Google Scholar 

  8. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20:785–98. doi:10.1016/j.immuni.2004.05.010.

    Article  PubMed  CAS  Google Scholar 

  9. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetescher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697–710. doi:10.1084/jem.190.11.1697.

    Article  PubMed  CAS  Google Scholar 

  10. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48:3475–86. doi:10.1002/art.11354.

    Article  PubMed  Google Scholar 

  11. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005;115:3083–92. doi:10.1172/JCI25265.

    Article  PubMed  CAS  Google Scholar 

  12. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol. 2005;62:421–8. doi:10.1111/j.1365-3083.2005.01688.x.

    Article  PubMed  CAS  Google Scholar 

  13. Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136:309–14. doi:10.1111/j.1365-2141.2006.06431.x.

    Article  PubMed  CAS  Google Scholar 

  14. Zhou Z, Chen Z, Li H, Chen X, Xu J, Gu D, et al. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity. 2008;42:112–9. doi:10.1080/08916930802397848.

    Article  Google Scholar 

  15. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79:504–22. doi:10.4065/79.4.504.

    Article  PubMed  Google Scholar 

  16. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Guqliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMAexperience. Blood. 2007;109:1402–7. doi:10.1182/blood-2005-12-015222.

    Article  Google Scholar 

  17. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994;330:1560–4. doi:10.1056/NEJM199406023302203.

    Article  PubMed  CAS  Google Scholar 

  18. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831–6. doi:10.1056/NEJMoa030254.

    Article  PubMed  CAS  Google Scholar 

  19. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93. doi:10.1182/blood-2008-07-162503.

    Article  PubMed  CAS  Google Scholar 

  20. Michael W, Graham W, Dempfle HL. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:1–10. doi:10.1093/nar/30.1.1.

    Article  Google Scholar 

  21. Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, et al. Serum levels of BAFF are increased in bullous pemphigoid but not pemphigus vulgaris. Br J Dermatol. 2006;155:330–6. doi:10.1111/j.1365-2133.2006.07305.x.

    Article  PubMed  CAS  Google Scholar 

  22. Reyes LI, León F, González P, Rozas MF, Labarca C, Segovia A, et al. Dexamethasone inhibits BAFF expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cytokine. 2008;42:170–8. doi:10.1016/j.cyto.2007.12.005.

    Article  PubMed  CAS  Google Scholar 

  23. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000;192:1453–66. doi:10.1084/jem.192.10.1453.

    Article  PubMed  CAS  Google Scholar 

  24. Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol. 2002;32:2004–10. doi:10.1002/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5.

    Article  PubMed  CAS  Google Scholar 

  25. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192:953–64. doi:10.1084/jem.192.7.953.

    Article  PubMed  CAS  Google Scholar 

  26. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97:198–204. doi:10.1182/blood.V97.1.198.

    Article  PubMed  CAS  Google Scholar 

  27. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9. doi:10.1182/blood-2003-08-2672.

    Article  PubMed  CAS  Google Scholar 

  28. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–4. doi:10.1038/nm921.

    Article  PubMed  CAS  Google Scholar 

  29. Olsson B, Andersson PO, Jacobsson S, Carlsson L, Wadenvik HS. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost. 2005;93:139–44.

    PubMed  CAS  Google Scholar 

  30. Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103:2645–7. doi:10.1182/blood-2003-07-2268.

    Article  PubMed  CAS  Google Scholar 

  31. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007;79:310–6. doi:10.1111/j.1600-0609.2007.00917.x.

    Article  PubMed  CAS  Google Scholar 

  32. Guo C, Chu X, Shi Y, He W, Li L, Wang L, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 2007;27:557–62. doi:10.1007/s10875-007-9111-1.

    Article  PubMed  CAS  Google Scholar 

  33. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–64. doi:10.1146/annurev.immunol.21.120601.141152.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from National Natural Science Foundation of China (30600259, 30600680, 30770922, 30800491, and 30801258), National Basic Research Program of China (973 Program No. 2009 CB 521904), Foundation for the Author of National Excellent Doctoral Dissertation of PR China (200561), Program for New Century Excellent Talents in University (NCET-07-0514), Key Project of Chinese Ministry of Education (109097), Key Clinical Research Project of Public Health Ministry of China 2007-2009, Commonweal Trade for Scientific Research (200802031), and Taishan scholar project funding.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yan Shi.

Additional information

Xiao-juan Zhu, Yan Shi, and Jian-zhi Sun contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhu, Xj., Shi, Y., Sun, Jz. et al. High-Dose Dexamethasone Inhibits BAFF Expression in Patients with Immune Thrombocytopenia. J Clin Immunol 29, 603–610 (2009). https://doi.org/10.1007/s10875-009-9303-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-009-9303-y

Keywords

Navigation